|
2 Companies |
|
3 Products |
|
3 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
13 News |
|
- | deferasirox tablet for oral suspension / Generic mfg.
Biomarker, Enrollment change, Trial withdrawal: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 4, 2024
P2, N=0, Withdrawn, Sponsor: Haukeland University Hospital
N=50 --> 0 | Terminated --> Withdrawn
- | Phase classification: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Apr 12, 2017
P4, N=243, Completed, Sponsor: Novartis Pharmaceuticals
N=50 --> 0 | Terminated --> Withdrawn Phase classification: P=N/A --> P4
- deferasirox tablet for oral suspension / Generic mfg.
Biomarker, Trial termination, Trial primary completion date: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 23, 2017
P2, N=50, Terminated, Sponsor: Haukeland University Hospital
Phase classification: P=N/A --> P4 Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm
- deferoxamine / Generic mfg., deferiprone / Generic mfg.
Trial completion: Amlodipine for Myocardial Iron in Thalassemia (clinicaltrials.gov) - Dec 30, 2015
P2/3, N=20, Completed, Sponsor: Aga Khan University
Recruiting --> Terminated | Trial primary completion date: Mar 2014 --> Jan 2017; Failure to recruit patients with hemochromatosis to the Deferasirox arm Active, not recruiting --> Completed
- ||| Trial completion: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Dec 30, 2015
P=N/A, N=228, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- || Trial primary completion date: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=250, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Sep 2014 --> Jun 2015
- deferoxamine / Generic mfg., deferiprone / Generic mfg.
Enrollment closed, Trial primary completion date: Amlodipine for Myocardial Iron in Thalassemia (clinicaltrials.gov) - Jan 15, 2015
P2/3, N=20, Active, not recruiting, Sponsor: Aga Khan University
Trial primary completion date: Sep 2014 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Sep 2015
- || Trial primary completion date: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Apr 30, 2014
P=N/A, N=250, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Jul 2014 --> Sep 2014
- deferoxamine / Generic mfg., deferiprone / Generic mfg.
New P2/3 trial: Amlodipine for Myocardial Iron in Thalassemia (clinicaltrials.gov) - Feb 17, 2014
P2/3, N=20, Recruiting, Sponsor: Aga Khan University
- | deferasirox tablet for oral suspension / Generic mfg.
Biomarker, New P2 trial: Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 2, 2013
P2, N=50, Recruiting, Sponsor: Haukeland University Hospital
- ||| Enrollment open: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Jun 30, 2013
P=N/A, N=250, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- glatiramer acetate / Generic mfg.
Trial completion: GASWI: A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=60, Completed, Sponsor: University at Buffalo
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Enrollment change: An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=250, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=350 --> 250
- | Rebif (human IFN-?-1a) / EMD Serono
Trial completion, MRI, Metastases: Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial (clinicaltrials.gov) - Apr 2, 2012
P4, N=38, Completed, Sponsor: EMD Serono
N=350 --> 250 Active, not recruiting --> Completed